Fresenius Medical Care AG & Co. KGaA (ETR:FME) Given a €79.00 Price Target by Goldman Sachs Group Analysts

Goldman Sachs Group set a €79.00 ($91.86) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note released on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other analysts have also commented on FME. HSBC set a €87.00 ($101.16) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Wednesday, February 13th. Barclays set a €68.00 ($79.07) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a neutral rating in a report on Monday, February 18th. JPMorgan Chase & Co. set a €83.20 ($96.74) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Monday, February 18th. UBS Group set a €82.00 ($95.35) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Wednesday, February 20th. Finally, Nord/LB set a €82.00 ($95.35) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Wednesday, February 20th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of €82.81 ($96.29).

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at €66.70 ($77.56) on Thursday. The firm has a market cap of $20.32 billion and a P/E ratio of 10.39. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €55.44 ($64.47) and a 12 month high of €91.74 ($106.67). The company has a debt-to-equity ratio of 100.05, a quick ratio of 0.67 and a current ratio of 1.02.



Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Further Reading: What is Blockchain?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.